论文部分内容阅读
试验分析了小鼠在感染大肠杆菌O157∶H7期间肠道微生物区系的变化及灌胃瑞士乳杆菌KLDS1.8701对其肠道微生物的调节作用。结合小鼠表象特征,探讨了瑞士乳杆菌KLDS1.8701对小鼠腹泻的治疗效果。试验将小鼠分成3组,分别是PBS对照组、大肠杆菌-PBS对照组和大肠杆菌-KLDS1.8701组,对试验组小鼠连续7 d灌胃大肠杆菌致病后,再连续7 d灌胃瑞士乳杆菌KLDS1.8701,期间采集小鼠粪便利用选择性培养基对菌群作平板计数。结果表明:瑞士乳杆菌KLDS 1.8701可以极显著地提高感染大肠杆菌O157∶H7小鼠的体重(p<0.01);小鼠在感染大肠杆菌O157∶H7后粪便中致病性大肠杆菌、肠杆菌和肠球菌等条件致病菌数量显著增加(p<0.05),乳酸菌和双歧杆菌等有益菌显著减少(p<0.05);灌胃瑞士乳杆菌KLDS1.8701后,小鼠粪便中致病性大肠杆菌、肠杆菌和肠球菌均显著降低(p<0.05),而乳酸菌和双歧杆菌增加极显著(p<0.01)。试验证实瑞士乳杆菌KLDS1.8701对感染大肠杆菌O157∶H7小鼠肠道微生物平衡具有一定的调节作用,对其引起的腹泻有一定的治疗效果。
The changes of gut microbiota in mouse infected with Escherichia coli O157: H7 and the regulation of gut microbiota by Lactobacillus helveticus KLDS1.8701 were analyzed. Combined with the phenotypic characteristics of mice, the therapeutic effect of Lactobacillus helveticus KLDS1.8701 on mice diarrhea was discussed. The mice were divided into three groups: PBS control group, Escherichia coli-PBS control group and E. coli-KLDS1.8701 group. The mice in the experimental group were challenged with E. coli for 7 consecutive days, Stomach Lactobacillus helveticus KLDS1.8701 during which mouse feces were collected. Plate count was counted on the flora using selective medium. The results showed that Lactobacillus helveticus KLDS 1.8701 could significantly increase the body weight of E. coli O157:H7 mice infected with E. coli O157: H7 (P <0.01) Enterococcus faecalis and other conditions significantly increased the number of pathogens (p <0.05), Lactobacillus and bifidobacteria and other beneficial bacteria was significantly reduced (p <0.05); intragastric administration of Lactobacillus helveticus KLDS1.8701 mice stool pathogenic large intestine Bacillus, Enterobacter and Enterococcus were significantly reduced (p <0.05), while lactobacilli and bifidobacteria increased significantly (p <0.01). The experiment confirmed that Lactobacillus helveticus KLDS1.8701 has a certain regulatory effect on the intestinal microflora of E. coli O157: H7 infected mice and has certain curative effect on diarrhea caused by it.